Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

BRO vs WST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

BRO Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 5–5 Matrix Metrics)

BRO Overall Winner 6-Pillar Tally: BRO 6 – 0 WST Matrix Metrics: BRO 5 – 5 WST

As of Nov 20, 2026, Brown & Brown, Inc. (BRO) is the stronger overall head-to-head candidate over West Pharmaceutical Services, Inc. (WST) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BRO carries a Unified Composite Score of 44.0/100 (HOLD) at $73.07 (15.4x Forward P/E, 26.8% operating margin), whereas WST carries 33.2/100 (SELL) at $390.30 (37.5x Forward P/E, 22.9% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About BRO vs WST
BRO NYSE Head-to-Head Winner
Brown & Brown, Inc.
Insurance Agents, Brokers & Service
$73.07
+1.0% 1D
Market Cap $24.0B
TTM Revenue $6.81B
Forward P/E 15.4x
Beta / 30D Vol -0.48β · 38% Vol
Unified Composite Score
44.0 / 100 HOLD
Tech 44.0 Fund 49.0 Flow 57.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 57
RSI-14: 57.3 · SMA20: $71.31 · SMA50: $67.38
WST NYSE
West Pharmaceutical Services, Inc.
Surgical & Medical Instruments & Apparatus
$390.30
-1.61% 1D
Market Cap $27.6B
TTM Revenue $3.40B
Forward P/E 37.5x
Beta / 30D Vol 0.46β · 27% Vol
Unified Composite Score
33.2 / 100 SELL
Tech 35.0 Fund 33.0 Flow 54.0 Mom 1.1
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 43
RSI-14: 43.2 · SMA20: $406.55 · SMA50: $386.53

6-Pillar Scorecard Institutional Category Breakdown (BRO 6 – 0 WST)

Columns: Metric · BRO · WST
1. Valuation Multiples BRO
Forward P/E 15.4x 37.5x
Trailing P/E 23.0x 44.5x
PEG Ratio 1.88x 2.94x
EV / Revenue 4.5x 8.1x
2. Growth & Scale BRO
Revenue Growth (YoY) +9.7% +8.7%
Earnings Growth (YoY) -1.0% +57.3%
TTM Revenue (USD) $6.81B $3.40B
Market Cap $24.0B $27.6B
3. Profitability & Quality BRO
Gross Margin 49.8% 37.6%
Operating Margin 26.8% 22.9%
Net Profit Margin 17.9% 18.8%
Return on Equity (ROE) 9.8% 21.2%
4. Balance Sheet & Cash Flow BRO
Cash Generation (TTM) $1.49B $453M
Cash Flow Margin 21.8% 13.3%
Net Cash / Leverage $6.94B Net Debt (0.64x D/E) $159M Net Cash
Dividend Yield 0.91% 0.22%
5. Options & Positioning BRO
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 30.8% (8th %ile) 28.2% (11th %ile)
Put/Call OI Skew 0.08x (Call-Skewed) N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat BRO
OpEx & R&D Intensity 23.0% of Rev ($1.57B) 14.7% of Rev ($499M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Scale & Operating Efficiency Moat
Supply-Chain Role Insurance Brokers Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: BRO (5) vs WST (5)
Institutional Metric BRO WST Criterion Row Edge
Market Capitalization
Scale
$24.0B $27.6B Larger Scale WST
Trailing P/E Ratio
Valuation
23.0x 44.5x Lower Multiple BRO
Forward P/E Ratio
Valuation
15.4x 37.5x Lower Multiple BRO
Revenue Growth (YoY)
Growth
+9.7% +8.7% Higher Growth BRO
Operating Margin (TTM)
Profitability
26.8% 22.9% Higher Margin BRO
Net Profit Margin
Profitability
17.9% 18.8% Higher Margin WST
Return on Equity (ROE)
Capital Efficiency
9.8% 21.2% Higher ROE WST
52-Week Range Position
Momentum
67% ($54–$83) 78% ($224–$438) Stronger Trend WST
Beta / 30D Volatility
Risk Regime
-0.48β · 38% Vol 0.46β · 27% Vol Lower Realized Risk WST
Unified Institutional Score
Composite Signal
44.0 / 100 (HOLD) 33.2 / 100 (SELL) Higher Composite BRO
Trailing 12M Revenue (USD)
Operating Scale
$6.81B $3.40B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
49.8% 37.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.88x PEG · 4.5x EV/Rev 2.94x PEG · 8.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.49B ($6.94B Net Debt (0.64x D/E)) $453M ($159M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon WST +0.96 pp
BRO: -1.91% · WST: -0.95%
3M Horizon WST +12.55 pp
BRO: -2.08% · WST: +10.47%
6M Horizon BRO +3.02 pp
BRO: +26.37% · WST: +23.35%
1Y Horizon WST +58.62 pp
BRO: -7.28% · WST: +51.34%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period BRO Revenue WST Revenue BRO Op. Margin WST Op. Margin Margin Leader
FY2018 $2.01B $1.72B 17.1% 14.0% BRO
FY2019 $2.39B $1.84B 16.7% 16.1% BRO
FY2020 $2.61B $2.15B 18.4% 19.0% WST
FY2021 $3.05B $2.83B 19.2% 26.6% WST
FY2022 $3.57B $2.89B 18.8% 25.4% WST
FY2023 $4.26B $2.95B 20.5% 22.9% WST
FY2024 $4.80B $2.89B 20.7% 19.7% BRO
FY2025 $5.90B $3.07B 17.9% 19.0% WST

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
BRO CONSOLIDATION
81d in phase · OBV NEUTRAL
Current IV 30.8%
IV Percentile 8th %ile
Put/Call OI Skew 0.08x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact BRO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
WST UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 28.2%
IV Percentile 11th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact WST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $396.39 · IV 28.3%

WST Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($39,639)

Compare $39,639 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 28.3% ATM IV.

5-DAY BULLISH SWING Liq C

Dec 18 $410 / $420 Bull Call Spread

Buy 1x $410C · Sell 1x $420C · 29d

Net Entry $603 Debit
T+5d @ +5% Move +$152 (+25%)
Max Risk / Buffer $603 Capped
5d Edge & Liquidity 0.6x R:R · Liq C
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Jan 15 '27 $370 / $350 Bull Put Spread

Sell 1x $370P · Buy 1x $350P · 57d

Net Entry $163 Credit
Max Credit / Yield +$163 (+8.9% RoM)
Max Risk / Buffer -7.1% Cushion ($1,837 Mgn)
5d Edge & Liquidity 80% PoP · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
BRO Moat Profile Scale & Operating Efficiency Moat
Insurance Brokers Operator
Competes within the Insurance Brokers value chain with $24.0B market capitalization and 26.8% operating margin.
OpEx & R&D Reinvestment 23.0% of Rev ($1.57B)
90D Engineering Disclosures 0 Published
WST Moat Profile Scale & Operating Efficiency Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $27.6B market capitalization and 22.9% operating margin.
OpEx & R&D Reinvestment 14.7% of Rev ($499M)
90D Engineering Disclosures 0 Published

Investor FAQ BRO vs WST Key Questions & Quantitative Answers

As of Nov 20, 2026, Brown & Brown, Inc. (BRO) is the stronger overall head-to-head candidate over West Pharmaceutical Services, Inc. (WST) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). BRO carries a Unified Composite Score of 44.0/100 (HOLD) at $73.07 (15.4x Forward P/E, 26.8% operating margin), whereas WST carries 33.2/100 (SELL) at $390.30 (37.5x Forward P/E, 22.9% operating margin). Technically, BRO sits in a Neutral phase (RSI 57.3, CONSOLIDATION options structure) and WST sits in a Neutral phase (RSI 43.2, UNCLASSIFIED options structure).

BRO leads the Growth & Scale pillar: BRO posts +9.7% YoY revenue growth and -1.0% YoY earnings growth on $6.81B TTM revenue (49.8% gross margin, 26.8% operating margin), compared with WST at +8.7% YoY revenue growth and +57.3% YoY earnings growth on $3.40B TTM revenue (37.6% gross margin, 22.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), BRO cumulative revenue shifted +193.5% while WST shifted +78.5%. In operating R&D and SG&A reinvestment, BRO deploys 23.0% of Rev ($1.57B) (0 90-day corporate R&D disclosures) versus 14.7% of Rev ($499M) (0 disclosures) for WST.

BRO screens cheaper on headline valuation multiples. BRO trades at 15.4x Forward P/E, 23.0x Trailing P/E, 1.88x PEG, and 4.5x EV/Revenue (21.8% FCF margin), whereas WST trades at 37.5x Forward P/E, 44.5x Trailing P/E, 2.94x PEG, and 8.1x EV/Revenue (13.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against BRO (9.8% ROE) versus WST (21.2% ROE) capital efficiency.

In options market volatility and institutional positioning, BRO carries 30.8% implied volatility (8th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (-0.48β · 38% Vol realized risk). By comparison, WST carries 28.2% implied volatility (11th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.46β · 27% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.